Skip to main content
Top
Published in: Calcified Tissue International 1/2003

01-07-2003 | Clinical Investigations

Stimulated Type I Collagen Turnover in Patients With Giant Cell Tumor of Bone

Authors: H. Nakashima, H. Sugiura, Y. Nishida, Y. Yamada, I. Tabata, N. Ishiguro

Published in: Calcified Tissue International | Issue 1/2003

Login to get access

Abstract

The aim of this study was to determine type I collagen turnover in giant cell tumor of bone (GCT) by biochemical markers of type I procollagen aminoterminal propeptide (PINP) and type I collagen carboxyterminal telopeptide (ICTP) as synthesis and degradation markers, respectively. The serum concentrations of PINP and ICTP were measured in 11 patients with GCT using radioimmunoassay, and analyzed by the correlation to the grades of GCT progression described by Campanacci. Serum of the 11 healthy subjects was available for comparison. The serum concentration of PINP was significantly higher in patients with GCT (82.4 ± 46.2 ng/ml) than in controls (40.8 ± 12.1 ng/ml) (P < 0.01), and that of ICTP was also significantly higher in GCT (5.3 ± 2.0 ng/ml) than in controls (3.2 ± 0.8 ng/ml) (P < 0.01). In GCT, the PINP concentration of grade 3 (127.6 ± 38.8 ng/ml) was higher than that in grade 1 patients (46.9 ± 4.8 ng/ml) (P < 0.01). ICTP concentration of both grades 2 (7.1 ± 1.4 ng/ml) and 3 (5.8 ± 1.8 ng/ml) patients was significantly higher than that of grade 1 (3.5 ± 0.6 ng/ml) patients (P < 0.01, P < 0.05, respectively). Two cases of serum concentration of PINP and ICTP after resection of GCT demonstrated that these biomarkers decreased to the control levels in the absence of GCT. Our results indicated that type I collagen turnover evaluated by ICTP and PINP was stimulated in the presence of GCT. Moreover, this enhanced metabolic turnover reflects the grade of GCT.
Literature
1.
go back to reference Zheng, MH, Robbins, P, Xu, J, Huang, L, Wood, DJ, Papadimitriou, JM 2001The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclastos.Histol Histopathol16297307PubMed Zheng, MH, Robbins, P, Xu, J, Huang, L, Wood, DJ, Papadimitriou, JM 2001The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclastos.Histol Histopathol16297307PubMed
2.
go back to reference Salm, R, Sissonss, HA 1972Giant cell tumors of soft tissues.J Pathol1072732PubMed Salm, R, Sissonss, HA 1972Giant cell tumors of soft tissues.J Pathol1072732PubMed
3.
go back to reference Mirra, JM 1989Giant cell tumor.Mirra, JMPicci, PGold, RH eds. Bone tumors. Clinical, radiologic, and pathologic correlations.Lea & FebigerPhiladelphia941992 Mirra, JM 1989Giant cell tumor.Mirra, JMPicci, PGold, RH eds. Bone tumors. Clinical, radiologic, and pathologic correlations.Lea & FebigerPhiladelphia941992
4.
go back to reference Risteli, J, Niemi, S, Kauppila, S, Melkko, J, Risteli, L 1995Collagen propeptides as indicators of collagen assembly.Acta Orthop Scand6616PubMed Risteli, J, Niemi, S, Kauppila, S, Melkko, J, Risteli, L 1995Collagen propeptides as indicators of collagen assembly.Acta Orthop Scand6616PubMed
5.
go back to reference Risteli, L, Risteli, J 1993Biochemical markers of bone metabolism.Ann Med25385393PubMed Risteli, L, Risteli, J 1993Biochemical markers of bone metabolism.Ann Med25385393PubMed
6.
go back to reference Tahtela, R, Tholix, E 1996Serum concentrations type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy- and aminoterminal propeptide (PICP PINP) as markers of metastatic bone disease in breast cancer.Anticancer Res1622892294PubMed Tahtela, R, Tholix, E 1996Serum concentrations type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy- and aminoterminal propeptide (PICP PINP) as markers of metastatic bone disease in breast cancer.Anticancer Res1622892294PubMed
7.
go back to reference Kylmala, T, Tammela, TLJ, Risteli, L, Risteli, J, Kontturi, M, Elomaa, I 1995Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.Br J Cancer7110611064PubMed Kylmala, T, Tammela, TLJ, Risteli, L, Risteli, J, Kontturi, M, Elomaa, I 1995Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.Br J Cancer7110611064PubMed
8.
go back to reference Elomaa, I, Virkkunen, P, Risteli, L, Risteli, J 1992Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma.Br J Cancer66337341PubMed Elomaa, I, Virkkunen, P, Risteli, L, Risteli, J 1992Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma.Br J Cancer66337341PubMed
9.
go back to reference Blomqvist, C, Riateli, L, Risteli, J, Virkkunen, P, Sarna, S, Elomaa, I 1996Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.Br J Cancer7310741079PubMed Blomqvist, C, Riateli, L, Risteli, J, Virkkunen, P, Sarna, S, Elomaa, I 1996Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.Br J Cancer7310741079PubMed
10.
go back to reference Kobayashi, T, Gabazza, EC, Taguchi, O, Risteli, J, Risteli, L, Kobayashi, H, Yasui, H, Yuda, H, Sakai, T, Kaneko, M, Adachi, Y 1999Type I collagen metabolites as tumor markers in patients with lung carcinoma.Cancer8519511957CrossRefPubMed Kobayashi, T, Gabazza, EC, Taguchi, O, Risteli, J, Risteli, L, Kobayashi, H, Yasui, H, Yuda, H, Sakai, T, Kaneko, M, Adachi, Y 1999Type I collagen metabolites as tumor markers in patients with lung carcinoma.Cancer8519511957CrossRefPubMed
11.
go back to reference Tomer, G, Cohen, IJ, Kidron, D, Katz, K, Yosipovitch, Z, Meller, I, Zaizov, R 1999Prognostic factors in non-metastatic limb osteosarcoma: a 20-year experience of one center.Int J Oncol15179185PubMed Tomer, G, Cohen, IJ, Kidron, D, Katz, K, Yosipovitch, Z, Meller, I, Zaizov, R 1999Prognostic factors in non-metastatic limb osteosarcoma: a 20-year experience of one center.Int J Oncol15179185PubMed
12.
go back to reference Campanacci, M, Baldini, N, Boriani, S, Sundanese, A 1987Giant cell tumor of bone.J Bone Joint Surg69106114PubMed Campanacci, M, Baldini, N, Boriani, S, Sundanese, A 1987Giant cell tumor of bone.J Bone Joint Surg69106114PubMed
13.
go back to reference James, IE, Dodds, RA, Lee-Rykaczewski, E, Eicheman, CF, Connor, JR, Hart, TK, Maleeff, BE, Lackman, RD, Gowen, M 1996Purification and characterization of fully funfoional osteoclast precursors.J Bone Miner Res1116081618PubMed James, IE, Dodds, RA, Lee-Rykaczewski, E, Eicheman, CF, Connor, JR, Hart, TK, Maleeff, BE, Lackman, RD, Gowen, M 1996Purification and characterization of fully funfoional osteoclast precursors.J Bone Miner Res1116081618PubMed
14.
go back to reference Teot, LA, Regis, JO, Randy, NR, O’connell, JX, Fox, EJ, Hicks, DG 1996Extraosseous primary and recurrent giant cell tumors: transforming growth factor-β1 and β-2 expression may explain metaplastic bone formation.Human Pathol27625632 Teot, LA, Regis, JO, Randy, NR, O’connell, JX, Fox, EJ, Hicks, DG 1996Extraosseous primary and recurrent giant cell tumors: transforming growth factor-β1 and β-2 expression may explain metaplastic bone formation.Human Pathol27625632
Metadata
Title
Stimulated Type I Collagen Turnover in Patients With Giant Cell Tumor of Bone
Authors
H. Nakashima
H. Sugiura
Y. Nishida
Y. Yamada
I. Tabata
N. Ishiguro
Publication date
01-07-2003
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 1/2003
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-002-1060-3

Other articles of this Issue 1/2003

Calcified Tissue International 1/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine